Free Trial
NASDAQ:PSTV

Plus Therapeutics Q1 2025 Earnings Results & Report

Plus Therapeutics logo
$0.95 +0.18 (+23.32%)
As of 11/13/2026

Plus Therapeutics missed analyst expectations on both earnings and revenue in its Q1 2025 results, released May 30, 2025. The company reported EPS of -$14.00 versus the -$4.25 consensus estimate, while revenue of $1.06 million fell short of the $1.11 million estimate by $53.00 thousand.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Plus Therapeutics EPS Results

Actual EPS
-$14.00
Consensus EPS
-$4.25
Beat/Miss
Missed by -$9.75
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Plus Therapeutics Revenue Results

Actual Revenue
$1.06 million
Expected Revenue
$1.11 million
Beat/Miss
Missed by -$53.00 thousand
YoY Revenue Growth
N/A

Plus Therapeutics Q1 2025 Earnings FAQ

Plus Therapeutics (NASDAQ:PSTV) reported earnings of -$14.00 per share for Q1 2025, missing the consensus estimate of -$4.25. The report was announced on Friday, May 30, 2025.

Plus Therapeutics reported revenue of $1.06 million for Q1 2025, against a consensus estimate of $1.11 million.

Plus Therapeutics Earnings Headlines

Plus Therapeutics (NASDAQ:PSTV) Stock Falls 4.1% - What's Next?
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Plus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email.

About Plus Therapeutics

Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage biotechnology company developing targeted treatments and diagnostic tools for cancers affecting the central nervous system. Its work includes radiopharmaceutical therapies designed to deliver radiation to tumors while limiting exposure to surrounding healthy tissue.

The company’s lead therapeutic program is Rhenium-186 NanoLiposome (RNL), an investigational treatment being studied for cancers including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics also develops CNSide, a diagnostic platform intended to help detect and monitor cancer cells in cerebrospinal fluid.

Previously known as Cytori Therapeutics, the company adopted the Plus Therapeutics name in 2019. It is based in the United States and focuses its development programs on cancers of the brain and central nervous system.

View Plus Therapeutics Profile